PMID- 20022093
OWN - NLM
STAT- MEDLINE
DCOM- 20100310
LR  - 20171116
IS  - 1095-6859 (Electronic)
IS  - 0090-8258 (Linking)
VI  - 116
IP  - 3
DP  - 2010 Mar
TI  - RhoC expression level is correlated with the clinicopathological characteristics 
      of ovarian cancer and the expression levels of ROCK-I, VEGF, and MMP9.
PG  - 563-71
LID - 10.1016/j.ygyno.2009.11.015 [doi]
AB  - OBJECTIVE: To determine the clinicopathological significance of RhoC expression 
      in human ovarian cancer and its effect on the expression of vascular endothelial 
      growth factor (VEGF), Rho-associated coiled-coil-forming kinase (ROCK), and metal 
      matrix proteinases (MMPs). METHODS: Tissue samples from normal ovaries, benign 
      ovarian tumors, and epithelial ovarian cancer were collected. The mRNA and 
      protein expression levels of RhoC, ROCK-I, VEGF, and MMP9 were assessed using 
      reverse-transcriptase polymerase chain reaction (RT-PCR) and Western blot, and 
      compared to the clinicopathological characteristics of the sample of origin using 
      the Pearson method of correlation analysis. Small interfering RNA (siRNA) was 
      also used to target RhoC expression in the OVCAR3 and CaOV3 ovarian cancer cell 
      lines, after which cell invasion and migration assays were performed, and the 
      expression of ROCK-I, VEGF, and MMP9 was evaluated. RESULTS: The expression 
      levels of RhoC, ROCK-I, VEGF, and MMP9 mRNA and protein were significantly higher 
      in ovarian cancer, showing a correlation with clinical stage but not histological 
      type. RhoC expression was positively correlated with ROCK-I, VEGF, and MMP9 
      expression. Decreased RhoC expression in siRNA-targeted cells inhibited their 
      ability to invade and migrate, as well as inhibiting ROCK-I, VEGF, and MMP9 
      expression. CONCLUSION: The expression level of RhoC is correlated to clinical 
      stage and vascularization in ovarian cancer.
FAU - Zhao, Yang
AU  - Zhao Y
AD  - Department of Gynecology, First Affiliated Hospital of China Medical University, 
      Liaoning, China.
FAU - Zong, Zhi-hong
AU  - Zong ZH
FAU - Xu, Hui-mian
AU  - Xu HM
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Gynecol Oncol
JT  - Gynecologic oncology
JID - 0365304
RN  - 0 (Matrix Metalloproteinase Inhibitors)
RN  - 0 (RNA, Messenger)
RN  - 0 (RNA, Small Interfering)
RN  - 0 (VEGFA protein, human)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - EC 2.7.11.1 (rho-Associated Kinases)
RN  - EC 3.4.24.35 (Matrix Metalloproteinase 9)
RN  - EC 3.6.5.2 (RHOC protein, human)
RN  - EC 3.6.5.2 (rho GTP-Binding Proteins)
RN  - EC 3.6.5.2 (rhoC GTP-Binding Protein)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Cell Line, Tumor
MH  - Cell Movement/physiology
MH  - Female
MH  - Humans
MH  - Matrix Metalloproteinase 9/*biosynthesis/genetics
MH  - Matrix Metalloproteinase Inhibitors
MH  - Middle Aged
MH  - Neoplasm Invasiveness
MH  - Neovascularization, Pathologic/genetics/metabolism/pathology
MH  - Ovarian Neoplasms/blood supply/genetics/*metabolism/pathology
MH  - RNA, Messenger/biosynthesis/genetics
MH  - RNA, Small Interfering/administration & dosage/genetics
MH  - Transfection
MH  - Vascular Endothelial Growth Factor A/antagonists & 
      inhibitors/*biosynthesis/genetics
MH  - Young Adult
MH  - rho GTP-Binding Proteins/antagonists & inhibitors/*biosynthesis/genetics
MH  - rho-Associated Kinases/antagonists & inhibitors/*biosynthesis/genetics
MH  - rhoC GTP-Binding Protein
EDAT- 2009/12/22 06:00
MHDA- 2010/03/11 06:00
CRDT- 2009/12/22 06:00
PHST- 2009/07/13 00:00 [received]
PHST- 2009/10/31 00:00 [revised]
PHST- 2009/11/08 00:00 [accepted]
PHST- 2009/12/22 06:00 [entrez]
PHST- 2009/12/22 06:00 [pubmed]
PHST- 2010/03/11 06:00 [medline]
AID - S0090-8258(09)00956-1 [pii]
AID - 10.1016/j.ygyno.2009.11.015 [doi]
PST - ppublish
SO  - Gynecol Oncol. 2010 Mar;116(3):563-71. doi: 10.1016/j.ygyno.2009.11.015.